JMKX005425 / Shanghai Jeyou Pharmaceutical - LARVOL DELTA

Discovery of JMKX005425, a potent WRN inhibitor highly efficacious in multiple MSI-H gastric cancer models (AACR 2026) - "Furthermore, low dose of JMKX005425 in combination with irinotecan completed suppressed tumor growth in an MSI-H CDX model. In conclusion, JMKX005425 is a potent, selective WRN inhibitor and shows high efficacy in multiple MSI-H models, especially in GC PDX models, highlighting its potential as a promising treatment for MSI-H gastric cancer. JMKX005425 is current in a phase I dose escalation study in patients with advanced MSI-H/dMMR solid tumors in China (CTR20253477)."

MSI-H • Preclinical • Endometrial Cancer • Gastric Cancer • Microsatellite Instability • Oncology • Solid Tumor • MSI • WRN

A Study of JMKX005425 in Patients With MSI-H/dMMR Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=102 | Recruiting | Sponsor: Jemincare | Not yet recruiting ➔ Recruiting

dMMR • Enrollment open • Mismatch repair • MSI-H • Microsatellite Instability • Solid Tumor